

Isothiocyanates as H₂S-Releasing Agents and Their Cardioprotective Effects

Valentina Citi*, Angela Corvino, Ferdinando Fiorino, Francesco Frecentese, Elisa Magli, Elisa Perissutti, Vincenzo Santagada, Simone Brogi, Lorenzo Flori, Era Gorica, Lara Testai, Alma Martelli, Vincenzo Calderone, Giuseppe Caliendo and Beatrice Severino

*Department of Pharmacy, University of Pisa, Italy.

Published September 22, 2020

ABSTRACT

The endogenous gasotransmitter hydrogen sulfide (H₂S) is an important regulator of the cardiovascular system, particularly of myocardial function. Moreover, H₂S exhibits cardioprotective activity against ischemia/reperfusion (I/R) or hypoxic injury and is considered an important mediator of “ischemic preconditioning”. In this work, a small library of isothiocyanates was evaluated for the H₂S releasing properties; the compound named ISOTHIA25 has been selected to further investigate its protective activity both *in vitro* and *in vivo* experimental procedures of ischemia/reperfusion injury.

All the isothiocyanates were able to release H₂S in a cell-free environment. The computational analysis lead to the selection of the compound named ISOTHIA25, which was able to release about 60 μM of H₂S when incubated at the concentration of 1 mM in the presence of L-Cysteine and which showed good solubility and a promising ADME profile. Furthermore, ISOTHIA25 was able to enter into the H9c2 cells and release H₂S in a concentration dependent manner. The protective effect was first evaluated using H9c2: the incubation of ISOTHIA25 before the treatment with H₂O₂, lead to a significant recovery in cell viability in a concentration dependent manner, with an almost complete recovery of the viability when incubated at the concentration of 1 μM.

The H₂S-donor ISOTHIA25 has been then tested in different experimental models of myocardial I/R: in Langendorff-perfused rat hearts subjected to I/R, ISOTHIA25 significantly improved the post-ischemic damage, limiting the tissue injury in a concentration dependent manner. Accordingly, also the LDH biomarker was reduced. This effect was antagonized by 5-hydroxydecanoic acid (a blocker of mitoKATP channels). Finally, in an *in vivo* model of acute myocardial infarction in rats, ISOTHIA25 significantly decreased I/R-induced tissue injury.

Isothiocyanate-based H₂S-releasing drugs like ISOTHIA25, can actually be considered a suitable pharmacological option in anti-ischemic therapy.

Isothia-25 exhibits H₂S-releasing properties both in a cell-free and in a cell-based assay, and due to this property, has cardioprotective effects *in vitro* and *in vivo*.

Keywords: Isothiocyanates, Cardioprotective Effects, Anti-ischemic therapy

Corresponding author: Valentina Citi, Department of Pharmacy, University of Pisa, Italy, E-mail: valentina.citi@unipi.it

Citation: Citi V, Corvino A, Fiorino F, Frecentese F, Magli E, et al. (2020) Isothiocyanates as H₂S-Releasing Agents and Their Cardioprotective Effects. Food Nutr Current Res, 3(S1): 3.

Copyright: ©2020 Citi V, Corvino A, Fiorino F, Frecentese F, Magli E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.